Attorney's Docket No.: 17109-002001/911

Applicant: Manuel Vega, et. al

Serial No.: 10/022,249

Amendment

AMENDMENTS TO THE SPECIFICATION:

Please replace the paragraph at page 112, line 26, - page 113, line 9 with the following:

Also provided are nucleic acid molecules and rAAV (any serotype) in which position 630 (or the corresponding position in another serotype; see Figs. 5 and the table above) has been changed. Changes at this position and the region around it lead to changes in the activity or in the quantities of the Rep or Cap proteins and/or the amount of AAV or rAAV produced in cells transduced with AAV encoding such mutants. Such mutations include tgc to gcg change (SEQ ID No. 721). Mutations at any position surrounding the codon position 630 that increase or decrease the Rep or Cap proteins quantities or activities are also provided. Methods using the rAAV (any serotype) that contain nucleic acid molecules with a mutation at position 630 or within 1, 2, 3 10 or more bases thereof for the intracellular expression of rep proteins or the rep gene mutants eovered by claims 10 to 13 described herein, for the production of AAV or rAAV (either in vitro, in vivo or ex vivo) are provided. In vitro methods include cell free systems, expression or replication and/or virus assembly.